GlobeNewswire Inc.··Gainey Mckenna & EglestonGossamer Bio Faces Class Action Over Failed PAH Study, Stock Plummets 80%
Gossamer Bio ($GOSS) faces class action lawsuit over failed PROSERA PAH trial; stock crashed 80% to $0.42 per share on February 23, 2026, amid allegations of misleading investor statements.
GOSSsecurities fraudclass action lawsuit